Clinical-trial AI is moving upstream into protocol and site design.
The important shift is not just patient matching. It is feasibility, site selection, protocol realism, and activation speed.
Executive read
- Clinical-trial AI is expanding from patient matching into site feasibility, protocol optimization, activation, and operating-risk prediction.
- The best systems combine real-world data, trial criteria, historical enrollment behavior, and operational constraints.
- The durable value is in making trial design more executable before expensive operational drag sets in.
Patient matching was only the first wave.
The next clinical-trials AI layer starts before recruitment. It asks whether a protocol is recruitable, which sites have realistic patient pools, where competing trials create friction, and whether the trial can be activated quickly enough to matter.
That is a more valuable question than matching one patient to one trial after the protocol is already fixed. It shifts AI from rescue mode to design mode.
Site feasibility is becoming a data product.
Recent market research frames AI-powered site feasibility around site selection, patient recruitment, protocol design, performance analytics, real-world data analytics, and CTMS integration. That breadth matters because trial performance is a system property, not a single matching problem.
The practical inputs are messy: claims, EHR extracts, free-text eligibility criteria, geography, historical enrollment, investigator relationships, and competing-trial burden.
DocTr is a useful signal for where the field is going.
The DocTr paper describes a cross-modal model that recommends clinicians for trials using patient encounter data, unstructured trial documents, and historical enrollment relationships from OpenPayments. Its evaluation covered 24,984 clinicians and 5,210 trials, with a reported 58% improvement in match similarity over baselines.
The notable part is not the metric alone. It is the formulation: clinician and site recommendation as a multi-objective optimization problem, including fairness, diversity, and competing-trial minimization.
The workflow layer is just as important as the model.
ConcertAI's ACT positioning is explicitly operational: study design, feasibility, site validation, activation, monitoring, and documentation. Whether any single vendor claim holds up in practice, this is the right product shape for the category.
Clinical development teams do not need another isolated score. They need an auditable workflow that turns protocol assumptions into site actions and course-corrects before recruitment misses become irreversible.